STAAR Surgical Co
NASDAQ:STAA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
STAAR Surgical Co
NASDAQ:STAA
|
US |
|
Action Construction Equipment Ltd
BSE:532762
|
IN |
|
Hnac Technology Co Ltd
SZSE:300490
|
CN |
|
A
|
APR Co Ltd
KRX:278470
|
KR |
|
Falck Renewables SpA
F:AA4
|
IT |
STAAR Surgical Co
In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures.
STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.
In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures.
STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.
Leadership: Interim Co-CEOs Warren Foust and Deborah Andrews are jointly leading STAAR while the Board conducts a CEO search.
Q4 Results: Total net sales were $57.8 million (Q4 2025) versus $49.0 million a year ago; China net sales in Q4 were $17.5 million versus $7.8 million a year ago.
China inventory: Management says distributor inventory in China has been reduced to contractual levels (and slightly below the referenced 6‑month level), improving visibility into in‑market demand.
Profitability progress: Gross margin expanded to 75.7% in Q4 2025 (from 64.7% prior year); adjusted EBITDA loss narrowed to $0.2 million from a $20.8 million loss a year ago.
Costs & run rate: Total Q4 operating expenses were $66.6 million, including $11.2 million of merger-related costs; operating expenses ex-merger/restructuring were $54.7 million (down 8.2% YoY). Management beat its $225 million second-half 2025 expense target and expects a similar ~$225 million operating expense run rate in 2026.
Manufacturing & tariffs: Swiss manufacturing (Nidau) is producing commercial product and is being scaled to support EVO+ in China to mitigate tariff exposure and increase supply resilience.
Outlook (qualitative): Management is targeting profitability in FY 2026, expects slightly lower gross margin in 2026 due to Swiss inventory cost and increased reserves, and plans cash generation to resume in H2 with year‑end 2026 cash higher than 2025.
